Articles tagged with Sepsis
A team of scientists has identified molecular biomarkers associated with sepsis, which could be used to predict patient outcomes and guide treatment. The study found that changes in CD52 expression were linked to good outcomes, while S100A9 acted as a driver of fatal sepsis.
Researchers have developed a sophisticated new tool to detect and identify rare and unknown viruses and potentially deadly bacterial pathogens. The algorithm helps isolate DNA sequences shared among related organisms, enabling faster detection and identification of pathogens in clinical or wildlife settings.
A mechanical engineering faculty-researcher at RIT is developing a microfluidic device to improve the detection of drug-resistant bacteria in blood, which can cause severe infection and death. The goal is to detect these strains early, allowing for prompt treatment and recovery.
A recent study published in Scientific Reports found that the degree of platelet reduction is more strongly linked to mortality risk in sepsis than absolute platelet count. The researchers also discovered that a significant decrease in platelet count increases the risks of bleeding and thrombosis development.
Studies on mice and septic patients show that a specific B lymphocyte subpopulation produces large amounts of CD39, leading to increased adenosine levels and reduced macrophage activity. This results in heightened susceptibility to opportunistic infections, with survivors experiencing a sevenfold higher risk of severe infections.
A recent study reveals that protein HSP27 plays a crucial role in regulating blood vessel leakage, which is a hallmark of sepsis. By targeting HSP27, researchers hope to develop drugs that can stabilize blood vessel barriers and prevent fluid loss.
A new study found that an early warning system for sepsis improved patient outcomes by alerting healthcare providers to administer antibiotics sooner. The system, implemented in the emergency department, resulted in increased survival rates and reduced hospital stays for patients with sepsis.
Researchers review advancements in biosensing technologies for neonatal sepsis diagnosis, highlighting the need for faster and more accurate methods. Biosensors offer a promising solution, detecting multiple parameters simultaneously with high sensitivity and accuracy.
A new USC study found that males are more susceptible to sepsis due to high degranulation activity, while females exhibit more NETosis, which can contribute to autoimmune disorders. The study highlights the importance of considering sex and age as predictors for immune response in personalized medicine.
A recent study found that a widely used sepsis prediction model performs poorly, correctly identifying patients at risk of sepsis only 63% of the time. The tool was developed based on billing codes, which can be inaccurate, and sent alerts to nearly 1 in 5 patients without actual sepsis.
Researchers aim to identify adrenal insufficiency in sepsis patients before glucocorticoid therapy. The study's findings suggest that supplementing glucocorticoids may not be necessary or beneficial for all patients, potentially leading to improved patient outcomes.
A large study shows that infants infected with Group B strep are twice as likely to have neurodevelopmental impairments and need special education compared to uninfected children. The study also found significant long-term effects, including cognitive impairment and higher rates of hospitalization, in up to one in twenty survivors.
Researchers found that higher platelet counts linked to better outcomes for patients with staph sepsis, while repurposed drugs protect platelets and improve survival of septic mice. The study suggests that boosting the immune system by protecting platelets could reduce mortality in staph sepsis.
US and UK digital COVID-19 symptom checkers failed to identify severe COVID-19, bacterial pneumonia, and sepsis, often advising patients to stay home. The study suggests that these symptom checkers may delay treatment for serious illness and confer an increased risk of morbidity and mortality.
A multi-disciplinary team at Harvard's Wyss Institute developed an electrochemical diagnostic sensor platform for multiplexed detection of clinically relevant biomarkers in whole blood. The device accurately detects three different sepsis biomarkers simultaneously and has the potential to revolutionize point-of-care diagnostics.
A virtual post-sepsis recovery program developed by Atrium Health has shown promise in helping sepsis survivors and those who have recovered from COVID-19. The program, known as STAR, uses low-tech telehealth methods to provide best-practice care for high-risk patients.
A new study published in the New England Journal of Medicine found that dexmedetomidine and propofol are equally effective and safe for light sedation in critically ill patients. The study, which enrolled 422 adults with sepsis, found similar patient outcomes between the two sedatives.
Galectin-1, a sugar-binding protein, may fuel inflammation and worsen sepsis in patients at risk. Researchers found elevated levels of galectin-1 in sepsis patients and suggest it as a potential biomarker for identifying those at risk.
A new study found that hospitals with better nurse-to-patient ratios had significantly lower sepsis death rates than those with higher ratios. Additionally, improved staffing resulted in cost savings through shorter hospital stays, which can be reinvested in improving nurse staffing.
A recent study published in The Lancet Child & Adolescent Health found that Black children diagnosed with severe sepsis have a 20% greater odds of death compared to their White and Hispanic peers. Additionally, 'other' insurance status was associated with increased mortality, and Black and Hispanic children had longer hospital stays.
A new rapid diagnostic system for sepsis is being developed at Penn State and Stanford University, which can identify fungal and bacterial pathogens within two hours. The five-year grant will allow researchers to bypass current blood culture steps and directly test pathogen susceptibility to antibiotics.
Doxycycline, an antibiotic, confers protection against sepsis by inhibiting mitochondrial protein production, reducing cell damage and promoting tissue repair. The study opens new possibilities for therapies targeting disease tolerance mechanisms to combat infections and diseases like sepsis.
Researchers at University of California San Diego School of Medicine discovered a molecule called Girdin (GIV) that acts as a brake on macrophages. The GIV-mimic peptide can shut down immune cells' overreaction, supporting a mechanism critical for survival in mouse models of sepsis and colitis.
A recent study aims to elucidate the link between B-type natriuretic peptide (BNP) and severe sepsis. Researchers found that BNP is increased in heart cells under stress, leading to lower cardiac output and promoting hypotension in septic patients.
A new online tool assesses risk factors for sepsis survivors to inform follow-up care pathways. The tool uses data from 120,000 patients and identifies eight key factors contributing to rehospitalization or death after discharge.
A systematic review of automated patient monitoring systems (PMSs) found that they can improve sepsis recognition and treatment in some studies, but the overall evidence is mixed. In total, 12 studies provided data on patient outcomes, with six showing reduced mortality rates.
Researchers at Harvard Medical School used acupuncture to regulate inflammatory responses and improve survival in mice with cytokine storm. The study found that site, intensity, and timing of treatment influenced the response.
A study published in PLOS Medicine found that patients with frailty, older age, and urinary tract infections have a higher risk of developing sepsis. Antibiotic therapy may reduce this risk, but unnecessary prescribing can contribute to antimicrobial resistance.
Researchers suggest live attenuated vaccines like MMR can activate immune cells to combat sepsis and lung inflammation associated with COVID-19. A proposed preventive measure could offer a 'no harm, no foul' benefit for vaccinated adults if infected.
Researchers found that patients with sepsis had higher levels of GDF15 in their blood, which was correlated with mortality. In mice without the GDF15 gene, the absence of this hormone improved survival rates after bacterial infection.
Researchers are conducting three studies to investigate important COVID-19 questions, including a trial of annexin A5 as a potential therapy for critically ill patients. A novel blood test for COVID-19 is also being developed using epitopes.
A five-year study has identified the mechanism behind the BCG vaccine's unexpected protection against diseases other than TB in newborns. The researchers found that BCG triggers a rapid increase in neutrophils, white blood cells that fight invading pathogens.
Researchers developed a ground-breaking method to detect sepsis 2-3 days before clinical symptoms appear using endogenous signals (biomarkers). The test has high accuracy and may increase survival chances for sepsis patients. Approval in the US FDA is underway, with clinical trials starting soon.
Rates of E. coli-related sepsis vary greatly between UK NHS regions and are linked to the presence of pathogenic E. coli types in sewage. The study found higher prevalence of E. coli B2 types in South Wales, which correlates with higher sepsis rates.
Researchers have developed an antibody treatment that improves survival in rodent models of sepsis by targeting a protein called tetranectin. The therapy boosts survival even when started late after sepsis onset, suggesting its potential for treating severe bacterial infections and secondary sepsis in COVID-19 patients.
A study of 13,000 urgent GP referrals found that higher early warning scores are associated with quicker ambulance transfers and faster hospital reviews. Patients with the highest scores were nearly five times more likely to have sepsis and eight times more likely to die within two days of admission.
Researchers propose a new therapeutic modality for sepsis by targeting cell-free chromatin in healthy cells. The study found that three cfCh-inactivating agents improved parameters related to sepsis, including increased survival rates in mice.
Researchers have identified two crucial surface proteins, SpyAD and Isp2, that contribute to Group A streptococcus fitness in the female genital tract. This discovery may lead to the development of effective treatments and vaccines for puerperal sepsis.
Researchers found that breast milk with higher levels of epidermal growth factor can activate intestinal cells to keep harmful gut bacteria from migrating into the bloodstream. This could provide a potential new tool to combat late-onset sepsis in premature babies.
A new next-generation sequencing technique using real-time nanopore sequencing can analyze tiny amounts of microbial cell-free DNA, offering accurate diagnosis of sepsis-causing agents within hours. The technique achieved a 3.5-fold increase in sequencing throughput and allowed for pathogen identification within minutes.
Researchers developed a novel treatment that compacts and stabilizes neutrophil extracellular traps (NETs) to enhance bacterial capture, resist degradation, and improve sepsis outcomes. The treatment improved survival in mice with sepsis by reducing severity of illness and decreasing bacteria levels.
Researchers developed a novel computational algorithm to track pediatric sepsis epidemiology, providing more accurate data on outcomes and incidence over time. The algorithm showed an increasing incidence of sepsis among hospital encounters and mortality rates remained stable.
A new portable biosensor developed by researchers at EPFL's School of Engineering can rapidly detect sepsis biomarkers in a patient's bloodstream, slashing diagnosis time from several days to just a few minutes. The device uses plasmonics technology and achieves accuracy on par with gold-standard laboratory methods.
A new study published in The Lancet reveals sepsis is responsible for an estimated 48.9 million global cases and 11 million deaths in 2017, representing a doubling of previous estimates.
Scientists at Ohio State University have created a treatment for late-stage sepsis using nanotechnology to transform donated immune cells into a powerful antibacterial drug. The therapy demonstrated significant improvements in survival rates and bacteria clearance in mouse models of sepsis.
Researchers found that energy-producing mitochondria in muscles were abnormal and showed signs of oxidative damage, contributing to chronic muscle weakness. The study suggests the need for antioxidant therapies or other treatments to restore mitochondrial health.
A national approach for pediatric sepsis surveillance has been developed, utilizing electronic health records to facilitate widespread tracking of rates and outcomes. The proposed approach includes a preliminary case definition adapted to address specific differences among infants and children.
A digital alert system has been introduced to monitor patients with sepsis, leading to lower odds of death and shorter hospital stays. The system has also increased the chances of receiving timely antibiotics, resulting in improved outcomes for patients.
Biomedical researchers at Cincinnati Children's Hospital Medical Center have developed a new rapid blood assay called PERSEVERE to detect and stratify sepsis. The test accurately predicts patient risk of death from sepsis, enabling early medical interventions with greater precision.
Researchers have developed a new way to measure white blood cell function, providing more accurate prognostic information for patients with sepsis. The technology assesses activation state and function of white blood cells from small blood samples, allowing for earlier diagnosis and treatment.
Dr. Judith Hellman has been awarded the American Society of Anesthesiologists' Excellence in Research Award for her groundbreaking research on sepsis and inflammatory critical illness. Her discoveries have led to improved understanding of inflammation, immune function, and potential treatments for sepsis.
A new rapid testing method is being used to improve antibiotic treatment for sepsis patients, enabling medical teams to make quicker and more targeted therapy choices. The study found that providing rapid drug susceptibility information can lead to better patient outcomes and less unnecessary broad-spectrum antibiotic use.
A randomized clinical trial found that high-dose intravenous vitamin C did not reduce organ failure, inflammation, or vascular injury in patients with sepsis and acute respiratory distress syndrome (ARDS). The study's limitations include underpowered detection of differences and insufficient dosage.
A new study published in JAMA found that treating septic patients with intravenous vitamin C infusions significantly reduced mortality and improved recovery times. The trial showed a 30% reduction in mortality at day 28 compared to the placebo group, and patients spent three fewer days in the ICU.
Researchers identified specific microRNAs that predict pneumonia complications, enabling early detection and intervention. The study found correlations between microRNA profiles and sepsis and respiratory failure in pneumonia patients.
A new study finds that drawing blood cultures after starting antimicrobial treatment can result in a significant loss of available clinical information. The study suggests that drawing blood cultures prior to treatment may be more effective in identifying the bacteria causing the infection and selecting the right antibiotic.
A new study has found that initiating antibiotics immediately before obtaining blood cultures significantly affects their sensitivity and ability to diagnose bacterial and fungal infections. This change in guidelines may reduce mortality rates from sepsis, a life-threatening condition with a 20% mortality rate.
A recent study published in Annals of Internal Medicine found that early blood sampling for microorganisms is critical to treating sepsis. Emergency rooms must follow sepsis guidelines, which demand trained personnel and proper equipment, to prevent organ damage and death.
A $40,000 grant from The Emergency Medicine Foundation is supporting a study to increase awareness among parents about sepsis signs in children. Researchers hope this will lead to improved recognition strategies and faster diagnosis of sepsis.
Researchers found that sevoflurane improved survival rates and reduced bacterial presence in organs of mice with induced sepsis compared to isoflurane or no anesthetic. The study suggests a critical role for the type of general anesthesia used in treating sepsis.